Vaxart Obtains $12,500,000 Series B Financing
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=20a8cc1b-778d-4116-bea9-d7eb9dd2bfd9&Preview=1 -
Date
3/4/2010 -
Company Name
Vaxart -
Mailing Address
600 Townsend St San Francisco, CA 94103 -
Company Description
The combination of adenovirus vector, adjuvant and oral administration will unlock the potential of vector-based vaccination, with applications in Avian Influenza response, biodefense vaccines, and second-generation versions of existing vaccines. The company is currently testing an avian flu vaccine. -
Website
http://www.vaxart.com -
Transaction Type
Venture Equity -
Transaction Amount
$12,500,000 -
Transaction Round
Series B -
Proceeds Purposes
The funding will be used to advance the Company’s lead product, an oral vaccine for Avian influenza, through Phase I clinical trials. -
M&A Terms
-
Venture Investor
Care Capital -
Venture Investor
Undisclosed
